Chime Biologics Supports Mabgeek to Advance MG-K10 into Phase III Trials and Enter the U.S. Market February 21, 2025, Shanghai – Chime Biologics, a leading global CDMO that enables its partners’ success in biologics, today announced its continued collaboration with Mabgeek in advancing MG-K10, a potential Best-in-Class therapy, a novel IL-4Rα-targeting antibody drug for atopic […]

Chime Biologics and Mabgeek Achieve MG-K10 PPQ Milestone, Advancing Atopic Dermatitis and Asthma Therapies Antibody Drug MG-K10 Late-Stage Clinical Trials and Commercialization -Process Performance Qualification (PPQ) validates robust manufacturing standards and is crucial for regulatory compliance -Marks a key step forward for the world’s first once-monthly IL-4Rα-targeting antibody therapeutic for Th2-driven diseases, with a strategic […]

Chime Biologics and Korean Listed Company MedPacto Form Strategic Partnership to Accelerate Global Biologics Development and Manufacturing October 28, 2024, Shanghai, China – Chime Biologics, a leading global CDMO that enables its partners’success in biologics, today announced a strategic collaboration with MedPacto, a South Korean clinically staged company listed on KOSDAQ (235980). MedPacto, known for […]